Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| DBVT | PRESS-RELEASE | bullish | 5/10 | DBV Technologies reported Q1 2026 EPS of $(0.11), beating consensus of $(0.12) by 8.3%, and revenue of $0.9M, beating $8 | Apr 30, 2026 |
| EBS | PRESS-RELEASE | mixed | 6/10 | Emergent BioSolutions reported Q1 2026 adjusted net income per diluted share of $0.21, beating the consensus estimate of | Apr 30, 2026 |
| CUE | PRESS-RELEASE | mixed | 6/10 | Cue Biopharma licensed global rights (ex-China) to Ascendant-221, a Phase 2 anti-IgE antibody for allergic diseases, fro | Apr 30, 2026 |
| AKBA | PRESS-RELEASE | neutral | 1/10 | Akebia Therapeutics, Inc. announced it will report its Q1 2026 results on May 7. | Apr 30, 2026 |
| IPSC | PRESS-RELEASE | neutral | 3/10 | Century Therapeutics announced an oral presentation at the ADA 86th Scientific Sessions (June 5-8, 2026) highlighting pr | Apr 30, 2026 |
| AXSM | PRESS-RELEASE | bullish | 8/10 | Axsome Therapeutics announced FDA approval of AUVELITY (dextromethorphan HBr/bupropion HCl) for agitation associated wit | Apr 30, 2026 |
| OPK | PRESS-RELEASE | neutral | 4/10 | OPKO Health announced an amendment to its Nicoya Therapeutics agreement, receiving a 15% equity stake in Nicoya in excha | Apr 30, 2026 |
| ENLV | PRESS-RELEASE | neutral | 4/10 | Enlivex announced that its RAIN token has been listed on the HTX cryptocurrency exchange (formerly Huobi), one of the to | Apr 30, 2026 |
| QNRX | PRESS-RELEASE | neutral | 1/10 | Quoin Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 7, 2026. | Apr 30, 2026 |
| TOMZ | PRESS-RELEASE | mixed | 6/10 | TOMI Environmental Solutions announced a non-binding LOI to merge with Carbonium Core, a nuclear-grade graphite producer | Apr 30, 2026 |
| NCEL | PRESS-RELEASE | bearish | 6/10 | NewcelX reported FY2025 results with a net loss of $8.3M (including $5.7M non-cash finance expenses) and cash of $2.2M. | Apr 30, 2026 |
| LXRX | PRESS-RELEASE | neutral | 1/10 | Lexicon Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 7, 2026. | Apr 30, 2026 |
| INMB | PRESS-RELEASE | neutral | 1/10 | INmune Bio, Inc. announced it will report its Q1 2026 results on May 7. | Apr 30, 2026 |
| PRQR | PRESS-RELEASE | neutral | 2/10 | ProQR announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Bo | Apr 30, 2026 |
| PVLA | PRESS-RELEASE | neutral | 1/10 | Palvella Therapeutics Inc. announced it will host a conference call on May 7, 2026 to discuss its Q1 2026 results. | Apr 30, 2026 |
| TGTX | PRESS-RELEASE | neutral | 1/10 | TG Therapeutics, Inc. announced it will host a conference call on May 6, 2026 to discuss its Q1 2026 results. | Apr 30, 2026 |
| ATHE | PRESS-RELEASE | neutral | 4/10 | Alterity Therapeutics reported Q3 FY26 progress, highlighting FDA alignment on key Phase 3 program elements for ATH434 i | Apr 30, 2026 |
| ACIU | PRESS-RELEASE | neutral | 5/10 | AC Immune reported Q1 2026 EPS of -$0.13, beating consensus of -$0.14 by 7.1%, while revenue was $1.1M (contract revenue | Apr 30, 2026 |
| PHAT | PRESS-RELEASE | mixed | 5/10 | Phathom reported Q1 2026 revenue of $58.3M (+104% YoY), beating the $56.8M consensus, but GAAP EPS of -$0.37 missed the | Apr 30, 2026 |
| ACIU | PRESS-RELEASE | bullish | 7/10 | AC Immune dosed the first patients in Cohort AD4 of the Phase 1b/2 ABATE trial for its anti-Abeta Alzheimer's immunother | Apr 30, 2026 |
| ARGX | PRESS-RELEASE | neutral | 1/10 | argenx SE announced it will report its Q1 2026 results on May 7, 2026. | Apr 30, 2026 |
| MESO | PRESS-RELEASE | bullish | 7/10 | Mesoblast reported Q3 FY2026 results with Ryoncil net revenue of $30.3M, bringing cumulative launch revenue to ~$100M. E | Apr 29, 2026 |
| VCNX | PRESS-RELEASE | neutral | 3/10 | Vaccinex released financial results for the year ended December 31, 2025, reporting an EPS of -$1.09 for Q3 2023, which | Apr 29, 2026 |
| MEOH | PRESS-RELEASE | neutral | 2/10 | Methanex declared a quarterly dividend of $0.185 per share, payable June 30, 2026, to shareholders of record on June 16, | Apr 29, 2026 |
| TLX | PRESS-RELEASE | bullish | 7/10 | Telix announces positive dosimetry data from Phase 2 OPTIMAL-PSMA trial of TLX597-Tx in mCRPC, showing low salivary glan | Apr 29, 2026 |
| SILO | PRESS-RELEASE | neutral | 2/10 | Silo Pharma issued a press release highlighting recent U.S. federal actions supporting psychedelic therapeutics, includi | Apr 29, 2026 |
| XTLB | PRESS-RELEASE | mixed | 7/10 | XTL Biopharmaceuticals announced a definitive agreement to acquire 100% of Psyga Bio Ltd., a psychedelic therapeutics co | Apr 29, 2026 |
| RNXT | PRESS-RELEASE | neutral | 1/10 | RenovoRx, Inc. announced it will host a conference call on May 14 to discuss its Q1 2026 results. | Apr 29, 2026 |
| CADL | PRESS-RELEASE | neutral | 3/10 | Candel Therapeutics entered into a commercialization agreement with EVERSANA to support the potential U.S. launch of agl | Apr 29, 2026 |
| URGN | PRESS-RELEASE | neutral | 1/10 | UroGen Pharma Ltd. announced it will report its Q1 2026 results on May 6, 2026. | Apr 29, 2026 |